Nasacort AQ Switch Rides On “Evolution Of Data” – Sanofi CMO
This article was originally published in The Tan Sheet
Executive Summary
Charles Hugh-Jones, Sanofi’s chief medical officer for North America, says the firm will present clinical and consumer use data to allay concerns about the safety of intranasal corticosteroids, at the upcoming FDA advisory committee meeting to discuss the Rx-to-OTC switch of Nasacort AQ.
You may also be interested in...
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
FDA’s Nonprescription Drugs Advisory Committee will meet July 31 to discuss Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ to OTC sale, to be indicated for relief of hay fever symptoms in adults and children.
NDAC Puts Hitch In Oxytrol Switch With Negative Self-Selection Vote
In a 6-5 vote, FDA’s Nonprescription Drugs Advisory Committee said Merck did not show that consumers can appropriately self-select to use Oxytrol for Women in an OTC setting. The company expects to hear from FDA on its Rx-to-OTC switch application by the end of January.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.